Perrigo Reaches Year Anniversary For First OTC Brand Switch With Sixth Packaging Approval

Latest FDA approval for mometasone furoate, 50-mcg metered spray, is for three 144-spray containers. Nasonex 24HR Allergy is Perrigo’s first OTC switch of national brand and first mometasone furoate offered nonprescription in US.

• Source: Shutterstock

Perrigo Company PLC reached the end of the first year of marketing its first Rx-to-OTC switch with the sixth approval for additional packaging options for the product, OTC Nasonex 24HR Allergy nasal spray.

The Dublin-based firm’s latest approval for the mometasone furoate, 50-mcg metered spray, from the US Food and Drug Administration came on

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rx-to-OTC Switch

More from Health